|
First line therapy
|
81 (100)
|
162 (100)
| |
|
Combinations
| | | |
|
-NRTI+PI
|
67 (83)
|
138 (85)
|
0.7
|
|
-NRTI+NNRTI
|
14 (17)
|
26 (16)
|
0.7
|
|
Duration; months (mean ± SD)
|
13.46 ± 10.23
|
16.67 ± 8.45
|
0.06
|
|
N° of patients who suspended
|
53 (66)
|
91 (56)
|
0.2
|
|
Cause of suspension
| | | |
|
-side effects
|
30 (56)
|
37 (41)
|
0.1
|
|
-viro-immunological failure
|
8 (15)
|
15 (17)
|
0.6
|
|
Second line therapy
|
45 (56)
|
91 (56)
|
1
|
|
Third line therapy
|
11 (14)
|
31 (19)
|
0.4
|
|
Total number of drug changes (mean ± SD)
|
2.1 ± 0.9
|
2.0 ± 0.6
|
0.8,
|
|
Adherent to the last drug regimen
|
68 (84)
|
118 (73)
|
0.08
|
|
Side effects to HAART
| | | |
|
dyslipidemia
|
32 (40)
|
55 (34)
|
0.5
|
|
digestive intolerance
|
26 (32)
|
58 (36)
|
0.6
|
|
lipodystrophy
|
12 (15)
|
23 (14)
|
0.7
|
|
hyperglycaemia
|
8 (10)
|
3 (2)
|
0.01
|
|
anaemia
|
8 (10)
|
3 (2)
|
0.01
|
